Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Gatell JM, et al. Among authors: domingo p. Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505. Clin Infect Dis. 2019. PMID: 29912307 Clinical Trial.
Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
Podzamczer D, Miró JM, Bolao F, Gatell JM, Cosín J, Sirera G, Domingo P, Laguna F, Santamaría J, Verdejo J. Podzamczer D, et al. Among authors: domingo p. Ann Intern Med. 1995 Aug 1;123(3):175-80. doi: 10.7326/0003-4819-123-3-199508010-00003. Ann Intern Med. 1995. PMID: 7598298 Clinical Trial.
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Podzamczer D, Miró JM, Ferrer E, Gatell JM, Ramón JM, Ribera E, Sirera G, Cruceta A, Knobel H, Domingo P, Polo R, Leyes M, Cosin J, Fariñas MC, Arrizabalaga J, Martínez-Lacasa J, Gudiol F. Podzamczer D, et al. Among authors: domingo p. Eur J Clin Microbiol Infect Dis. 2000 Feb;19(2):89-95. doi: 10.1007/s100960050436. Eur J Clin Microbiol Infect Dis. 2000. PMID: 10746493 Clinical Trial.
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Martínez E, et al. Among authors: domingo p. N Engl J Med. 2003 Sep 11;349(11):1036-46. doi: 10.1056/NEJMoa021589. N Engl J Med. 2003. PMID: 12968087 Free article. Clinical Trial.
Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA. Rodes B, et al. Among authors: domingo p. J Med Virol. 2005 Sep;77(1):23-8. doi: 10.1002/jmv.20395. J Med Virol. 2005. PMID: 16032728
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D; Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team. Ochoa de Echagüen A, et al. Among authors: domingo p. AIDS. 2005 Sep 2;19(13):1385-91. doi: 10.1097/01.aids.0000181010.85255.3c. AIDS. 2005. PMID: 16103769 Clinical Trial.
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM, Lopez JC, Podzamczer D, Peña JM, Alberdi JC, Martínez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santín M, Ribera E; GESIDA 04/98 Study Group. Miro JM, et al. Among authors: domingo p. Clin Infect Dis. 2006 Jul 1;43(1):79-89. doi: 10.1086/504872. Epub 2006 May 31. Clin Infect Dis. 2006. PMID: 16758422 Clinical Trial.
759 results